Twin Helix
Covid 19 Fighting Area
While the coronavirus pandemic (COVID-19) continues to evolve globally, many of us have inevitably been affected in our daily lives.
At this unprecedented time, full of challenges and uncertainties, Twin Helix is firmly committed to serving customers, the scientific community and anyone who needs our capabilities.
Covid 19 fighting area
| Name | Application | Purity | QC |
|---|---|---|---|
| S protein (RBD) mFc | IgM/lgG kit with Anti-Mouse antibody | > 90% | SDS-PAGE, WB, ELISA binding against ACE-2 |
| S protein (RBD) His | IgM/lgG kit with Anti-His antibody | > 90% | SDS-PAGE, WB, ELISA binding against ACE-2 |
Based on the above virtual screening results, and combined with the recent clinical reports, we have also obtained some valuable potential drugs for SARS-CoV-2, which can reduce drug development cycle by using drug relocation strategy.
| Compound | Information | Condition |
|---|---|---|
| Darunavir | Darunavir is an HIV protease inhibitor that is used in the treatment of AIDS and HIV infections. | FDA Approved |
| Remdesivir | Remdesivir is a nucleoside analogue, with effective antiviral activity (EC50 of 74 nM for SARS-CoV and MERS-CoV in HAE cells) | Clinical |
| Camostat mesilate | Camostat is a trypsin-like protease inhibitor and inhibits airway epithelial sodium channel (ENaC) function. | Approved/Preclinical |
| Baricitinib | Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. | FDA Approved |
| Favipiravir | Favipiravir (T-705), an effective and selective RNA-dependent RNA polymerase inhibitor, are applied to treat influenza virus infections. | Approved/Preclinical |
| Ribavirin | Ribavirin is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. | FDA Approved |
| Chloroquine diphosphate | Chloroquine is an aminoquinoline antimalarial and also is widely used as an autophagy inhibitor. Chloroquine also is an inhibitor of toll-like receptors (TLRs). | FDA Approved |
| Nitazoxanide | Nitazoxanide is a synthetic benzamide with antiprotozoal activity. Nitazoxanide exerts its antiprotozoal activity by interfering with the pyruvate ferredoxin/flavodoxin oxidoreductase dependent electron transfer reaction. | FDA Approved |
All screening collections in this category were designed to meet the requirements from global scientific research institutions and pharmaceutical companies to help speed up anti-COVID-19 drugs development. The compound libraries contain compounds that have been demonstrated to have anti-coronavirus activity or are broad-spectrum antiviral agents and compounds from virtual screening hits based on molecular docking with high affinity to 7 SARS-CoV-2 protein targets and 1 human ACE2.
| Library | Information | CAT No |
|---|---|---|
| Anti-COVID-19 Compound Library | A unique collection of 2448 compounds with confirmed anti-SARS-CoV-2 activity or potential activity and part of them are broad-spectrum antiviral agents. | L1710 |
| Anti-COVID-19 compound library (CADD) | A unique collection of 362 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening | L1711 |
| 3CLpro-Targeted compound library (CADD) | A unique collection of 161 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening | L1712 |
| ACE2-Targeted compound library (CADD) | A unique collection of 462 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening | L1713 |
| RBD-Targeted compound library (CADD) | A unique collection of 206 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening | L1714 |
| nsp16-Targeted compound library (CADD) | A unique collection of 281 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening | L1715 |
| PLpro-Targeted compound library (CADD) | A unique collection of 474 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening | L1716 |
| RdRP-Targeted compound library (CADD) | A unique collection of 464 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening | L1717 |
| X Domain-Targeted compound library (CADD) | A unique collection of 463 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening | L1718 |
| nsp15-Targeted compound library (CADD) | A unique collection of 470 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening | L1719 |
| Anti-COVID-19 Traditional Chinese Medicine Compound Library | A unique collection of 389 monomers from 60 TCM plants, a powerful tool for anti-COVID-19 drug discovery, can be used for HTS and HCS screening | L6720 |
Genscript cPass™
What is the cPass™ Technology?
The cPass™ technology allows for the rapid detection of total neutralizing antibodies (NAbs) in a sample by mimicking the interaction between the virus and the host cell. In order for a virus to infect a host cell, a viral receptor binding protein (RBD) first needs to interact with the host cell's membrane receptor protein (ACE2).
The virus-host interaction and subsequent viral infection of the host cell leads to the activation of an individual's immune response which generates a population of antibodies against the virus. Some of these antibodies can bind to the virus, but not necessarily block viral infection. Other antibodies can bind to the RBD in a way that blocks the interaction with the ACE2 receptor. The cPass™ technology helps to distinguish whether a sample contains NAbs that may specifically block the interaction and therefore the viral entry into the host cell.
Why choose cPass™ technology?
Why choose the cPass™ Technology?
The gold standard (virus neutralization assay) test for measuring Nabs requires the use of live virus, cells, highly skilled operators, and complex safety laboratory procedures (biosafety level 3) that are generally less sensitive and require several days to obtain results. In contrast, the cPass™ Neutralization Antibody Detection Kit can be rapidly conducted within an hour in most labs, and is also amenable to high throughput and fully automated testing.
Another key advantage of the cPass™ technology is that it is a highly specific and sensitive and in the same time isotype- and species-independent. Current antibody tests on the market are typically isotype-specific for just IgM or IgG, species specific for human antibodies only and cannot distinguish NAbs from other binding antibodies which do not possess neutralizing function.
Rapid Nasal swab Antigene COVID 19
While the coronavirus pandemic (COVID-19) continues to evolve globally, many of us have inevitably been affected in our daily lives.
The numbers in Italy and around the world unfortunately continue to grow, we are all waiting for the arrival of a new vaccine, but, for the next few months, we will still have to be very patient.
In the meantime, the only way to protect ourselves, is to track the contagions by proceeding as far as possible with mass screening, the scientific community in recent months has collected a huge amount of experience and, based on it, we focus on possible solutions in the field of rapid diagnostics.
Translated with www.DeepL.com/Translator (free version)
Fast, Easy, Safe
The new rapid test for COVID19 antigen is 35% more sensitive than traditional IgG/IgM immunoglobulin detection kits, requires no instrumentation and the swab is very gentle during the test on the patient, in fact just insert it in the nostrils for only 2, 5 cm deep and the results will be ready in about 15 minutes, making it a valuable tool for mass screening in different contexts such as schools, airports, ports and in all those contexts where tracking and control are essential to prevent the virus from spreading further within national borders.
Blot analysis of RBD Protein (His tag)
NCP-RBD-His binding Test
